

REMARKS

With entry of this amendment, the status of the claims is as follows:

| | |
|-----------------------|------------|
| Original: | 1-3 |
| Currently amended: | 5, 6 and 8 |
| Previously presented: | None |
| Canceled: | 4 and 7 |
| Withdrawn: | None |
| New: | 9-11 |

Note that in this context "Original" means the original claims entering the U.S. national phase. Original claim 1 was amended via an Article 19 amendment. Original claim 8 was also amended in the Article 19 amendment, and the current amendment of claim 8 is derived from claim 8 as it appears in the Article 19 amendment. With entry of this amendment, claims 1-3, 5, 6 and 8-11 are pending.

The specification has been amended to contain a reference to the United Kingdom application for which a benefit of priority is being claimed.

The multiple dependencies have been removed from claims 5, 6 and 8.

Use claims 4 and 7 have been canceled.

New claim 9 is a method for inhibition of hepatitis C virus polymerase, support for which can be found on page 22, lines 18-25 of the specification.

New claims 10 and 11 recite embodiments of claim 2. Support for these claims can be found in the specification as follows: page 5, lines 7 and 9; page 7; lines 4-18.

No new matter has been introduced by any of the changes to the specification and claims.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: October 3, 2005